Equities research analysts at Lazard Capital upgraded shares of Alkermes Inc. (NASDAQ: ALKS) from a "neutral" rating to a "buy" rating in a research note to investors on Wednesday.
Separately, analysts at UBS AG (NYSE: UBS) raised their price target on shares of Alkermes Inc. from $19.00 to $20.50 in a research note to investors on Friday, July 8th. They now have a "neutral" rating on the stock. Also, analysts at MKM Partners initiated coverage on shares of Alkermes Inc. in a research note to investors on Tuesday, June 21st. They set a "buy" rating and a $20.00 price target on the stock.
Shares of Alkermes Inc. traded up 0.83% during mid-day trading on Thursday, hitting $19.38. Alkermes Inc. has a 52 week low of $9.85 and a 52 week high of $18.77. The stock's 50-day moving average is $17.92 and its 200-day moving average is $14.70. The company has a market cap of $1.863 billion.
Alkermes Inc. last announced its quarterly results on Wednesday, May 18th. The company reported ($0.14) earnings per share (EPS) for the previous quarter, meeting the Thomson Reuters consensus estimate of ($0.14) EPS. The company’s quarterly revenue was up 32.7% on a year-over-year basis. On average, analysts predict that Alkermes Inc. will post $-0.06 EPS next quarter.
Alkermes, Inc. is an integrated biotechnology company. The Company is engaged in the business of developing, manufacturing and commercializing medicines for the treatment of prevalent, chronic diseases. Alkermes, Inc. develops, manufactures and commercializes VIVITROL for alcohol dependence and manufacture RISPERDAL CONSTA for schizophrenia and bipolar I disorder. Its pipeline includes extended-release injectable and oral products for the treatment of prevalent, chronic diseases, such as central nervous system (CNS), disorders, reward disorders, addiction, diabetes and autoimmune disorders. The Company has a research facility in Massachusetts and a commercial manufacturing facility in Ohio. RISPERDAL CONSTA is used for the treatment of schizophrenia and for the treatment of bipolar I disorder. VIVITROL is an extended-release MEDISORB formulation of naltrexone, as a once-monthly injectable medication for the treatment of alcohol dependence.
Stay on top of analysts' coverage with American Banking & Market News' daily email newsletter that provides a concise list of analysts' upgrades, analysts' downgrades and analysts' price target changes for each day.Click here to register.
